By a News Reporter-Staff News Editor at Drug Week -- A new study on Central Nervous System Diseases is now available. According to news reporting originating from Ulm, Germany, by NewsRx correspondents, research stated, "Nanocarriers can be useful tools for delivering drugs to the central nervous system (CNS). Their distribution within the brain and their interaction with CNS cells must be assessed accurately before they can be proposed for therapeutic use."
Our news editors obtained a quote from the research from the University of Ulm, "In this paper, we investigated these issues by employing poly-lactide-co-glycolide nanoparticles (NPs) specifically engineered with a glycopeptide (g7) conferring to NPs the ability to cross the blood brain barrier (BBB) at a concentration of up to 10% of the injected dose. g7-NPs display increased in vitro uptake in neurons and glial cells. Our results showthat in vivo administration of g7-NPs leads to a region-and cell type-specific enrichment of NPs within the brain. We provide evidence that g7-NPs are endocytosed in a clathrin-dependent manner and transported into a specific subset of early endosomes positive for Rab5 in vitro and in vivo. The differential Rab5 expression level is strictly correlated with the amount of g7-NP accumulation."
According to the news editors, the research concluded: "These findings show that g7-NPs can cross the BBB and target specific brain cell populations, suggesting that these NPs can be promising carriers for the treatment of neuropsychiatric and neurodegenerative diseases."
For more information on this research see: Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution. Journal of Controlled Release, 2014;174():195-201. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
The news editors report that additional information may be obtained by contacting A. Vilella, Univ Ulm, Inst Anat & Cell Biol, D-89069 Ulm, Germany. Additional authors for this research include G. Tosi, A.M. Grabrucker, B. Ruozi, D. Belletti, M.A. Vandelli, T.M. Boeckers, F. Forni and M. Zoli (see also Central Nervous System Diseases).
Keywords for this news article include: Ulm, Europe, Germany, Nanoparticle, Nanotechnology, Emerging Technologies, Central Nervous System Diseases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC